According to the Graphical Research new growth forecast report titled “Europe Gene Editing Market Size By Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), By Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), TALENs), By End-user (Biotech and Pharma Companies, Contract Research Organizations (CROs), Research Institutes), Industry Analysis Report, Country Outlook (UK, Germany, France, Spain, Russia, Italy, Poland, The Netherlands, Sweden)”, Estimated To Exceed USD 2.6 Billion By 2026
Surging demand for biotechnology in the European region will act as a positive impact rendering factor. Several European based biotechnology companies have elevated their expenditures and R&D operations in countries including Switzerland, France, Belgium and others. This enables the availability of technologically advanced gene editing techniques at a lower cost thereby, boosting the market progression. Moreover, considerable growth of biotechnology sector in developed European countries will provide numerous growth opportunities for gene editing industry growth. For instance, extensive usage of CRISPR-Cas9 gene editing tool for its simplicity and efficiency in gene slicing and other molecular processes will prove beneficial for the overall industry expansion over the analysis period.
The gene editing market, based on application is categorized into plant genetic engineering, animal genetic engineering and cell line engineering among others. The plant genetic engineering segment accounted for around 19% market share in 2019, owing to the availability of technologically advanced gene editing techniques utilized in modifying the plant genome. Plant genetic engineering technology has wide applications in crop protection. For instance, BT Cotton is one of the first genetically engineered crops having bacillus thuringiensis bacterial gene, incorporate into the cotton seeds utilizing gene editing techniques. The genetically modified plants provide nutritious food, high productivity and food with more desirable traits including potatoes, thus secures the segmental expansion.
Based on technology, the Europe gene editing industry is fragmented into CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), TALENs and others. The zinc finger nucleases accounted for more than USD 260 million revenue size in 2019. ZFNs are designed to target and cleave specific DNA sequences. This technology has additional benefits such as the mutations made by this technology are permeant and heritable. Also, the gene editing process involving zinc finger nucleases results in less complications and finds numerous applications in cell line optimization that will positively influence the segment growth.
On the basis of end-user, the market is divided into biotech and pharma companies, contract research organizations (CROs) and research institutes. Amongst them, research institutes segment is expected to grow at over 15% CAGR during the analysis period. Growing support of government and funding in research processes undertaken by scientists have substantially escalated the segmental growth. Furthermore, growing incidences of rare genetic diseases in the European region has resulted in higher demand for research activities for developing new therapies. Thus, high preference for gene editing in developing efficient drugs will propel segment progression.
UK gene editing market is estimated to witness over 21.5% market share in 2019. Increasing focus of prominent industry players on developing innovative gene editing technology will enhance gene editing industry growth. Rising government initiatives for spreading awareness regarding advanced gene therapies and surging rate of genetic as well as chronic disorders in the UK will foster the demand for gene editing techniques.
Some of the foremost business players operating in market include Agilent Technologies, EMD Millipore (Merck KGAa), Integrated DNA Technologies, Origene Technologies, Thermo Fisher Scientific, Horizon Discovery Ltd, Takara Bio, Agilent Technologies, Caribou Biosciences, CRISPR Therapeutics and others. These market contributors are undertaking different initiatives to deliver advanced aspects of gene editing methods. For instance, In June 2019, Allele Biotechnology and Alpine BioTherapeutics Corporation announced an agreement for developing induced pluripotent stem cells for treatment of retinal diseases. This strategy assisted the company in developing advanced product portfolio.
Europe gene editing market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2015 to 2026, for the following segments:
Market Size, By Application, 2015 - 2026 (USD Million)
- Cell line engineering
- Animal genetic engineering
- Plant genetic engineering
Market Share, By Technology, 2015 - 2026 (USD Million)
- Zinc Finger Nucleases (ZFNs)
Market Trends, By End-user, 2015 - 2026 (USD Million)
- Biotech and pharma companies
- Contract Research Organizations (CROs)
- Research institutes
The above information is provided for the following region and countries:
- The Netherlands